Ultrasound-Guided Trigger Point Injection for Serratus Anterior Muscle Pain Syndrome

2015 ◽  
Vol 5 (6) ◽  
pp. 99-102 ◽  
Author(s):  
Grisell Vargas-Schaffer ◽  
Michal Nowakowsky ◽  
Marzieh Eghtesadi ◽  
Jennifer Cogan
2021 ◽  
Author(s):  
Kyu-Ho Yi ◽  
Ji-Hyun Lee ◽  
Kyle K Seo ◽  
Hee-Jin Kim

Abstract The serratus anterior muscle is commonly involved in myofascial pain syndrome and is treated with many different injective methods. Currently, there is no definite injection point for the muscle. This study provides an ideal injection point for the serratus anterior muscle considering the intramuscular neural distribution using the whole mount staining method. A modified Sihler method was applied to the serratus anterior muscles (15 specimens). The intramuscular arborization areas were identified in terms of the anterior (100%), middle (50%), posterior axillary line (0%), and from the first to the ninth ribs. The intramuscular neural distribution for the serratus anterior muscle had the largest arborization patterns in the 5th to 9th rib portion between 50% and 70%, and the 1st to 4th rib portion had between 20% and 40%. Clinicians can administer safe and effective treatments with botulinum neurotoxin injections and other types of injections, following the methods in our study. We propose optimal injection sites in relation to the external anatomical line for the frequently injected facial muscles to facilitate the efficiency of botulinum neurotoxin injections. Lastly, these guidelines would assist practice more accurately without the harmful side effects of trigger point injections and botulinum neurotoxin injections.


Pain Medicine ◽  
2017 ◽  
Vol 18 (8) ◽  
pp. 1600-1602
Author(s):  
Alexander Bautista ◽  
Clairese Webb ◽  
Richard Rosenquist

2020 ◽  
Vol 16 ◽  
pp. 174480692098407
Author(s):  
Feihong Jin ◽  
Lianying Zhao ◽  
Qiya Hu ◽  
Feng Qi

Background Myofascial pain syndrome (MPS) is an important clinical condition that is characterized by chronic muscle pain and a myofascial trigger point (MTrP) located in a taut band (TB). Previous studies showed that EphrinB1 was involved in the regulation of pathological pain via EphB1 signalling, but whether EphrinB1-EphB1 plays a role in MTrP is not clear. Methods The present study analysed the levels of p-EphB1/p-EphB2/p-EphB3 in biopsies of MTrPs in the trapezius muscle of 11 MPS patients and seven healthy controls using a protein microarray kit. EphrinB1-Fc was injected intramuscularly to detect EphrinB1s/EphB1s signalling in peripheral sensitization. We applied a blunt strike to the left gastrocnemius muscles (GM) and eccentric exercise for 8 weeks with 4 weeks of recovery to analyse the function of EphrinB1/EphB1 in the muscle pain model. Results P-EphB1, p-EphB2, and p-EphB3 expression was highly increased in human muscles with MTrPs compared to healthy muscle. EphB1 (r = 0.723, n = 11, P < 0.05), EphB2 (r = 0.610, n = 11, P < 0.05), and EphB3 levels (r = 0.670, n = 11, P < 0.05) in the MPS group were significantly correlated with the numerical rating scale (NRS) in the MTrPs. Intramuscular injection of EphrinB1-Fc produces hyperalgesia, which can be partially prevented by pre-treatment with EphB1-Fc. The p-EphB1 contents in MTrPs of MPS animals were significantly higher than that among control animals (P < 0.01). Intramuscular administration of the EphB1 inhibitor EphB1-Fr significantly suppressed mechanical hyperalgesia. Conclusions The present study showed that the increased expression of p-EphB1/p-EphB2/p-EphB3 was related to MTrPs in patients with MPS. This report is the first study to examine the function of EphrinB1-EphB1 signalling in primary muscle afferent neurons in MPS patients and a rat animal model. This pathway may be one of the most important and promising targets for MPS.


2020 ◽  
Vol 28 (6) ◽  
pp. 694-701
Author(s):  
I.A. Arsenova ◽  
◽  
I.O. Pohodenko-Chudakova ◽  
M.A. Lar’kina ◽  
◽  
...  

Цель. Оценить эффективность инъекций в триггерные точки при лечении миофасциального болевого синдрома челюстно-лицевой области. Материал и методы. С 2014-2017 гг. было пролечено 124 человека с миофасциальным болевым синдромом лица, из них 76 женщин и 48 мужчин в возрасте от 19 до 62 лет. Кроме клинических и рентгенологических методов диагностики всем пациентам выполняли электромиографию и тестирование болей по визуальной аналоговой шкале боли (VAS). С целью купирования миофасциального болевого синдрома применялись методы традиционной терапии: шиновая терапия, коррекция окклюзии, медикаментозная и физиотерапия. При неэффективности традиционных методов выполнялись инъекции «Лимфомиозот» и «Траумель С» в триггерные точки по методике J. Kersschot (2010). Контрольные осмотры проводились через 1, 3, 6, 12 и 18 и 24 месяца после выполнения манипуляции. При контрольных осмотрах обращали внимание на жалобы пациентов, определяли интенсивность боли по VAS. Критерием положительных результатов лечения являлось отсутствие болей в покое и при функциях. Результаты. При стандартном лечении положительные результаты были получены у 86 из 124 человек (69,4%). Инъекции в триггерные точки, выполняемые при недостаточной эффективности лечения у 38 человек, привели к прекращению боли у 32 (84,2%) пациентов. Как показали наши наблюдения, длительный период без боли (в течение двух лет) наблюдали у 12 (37,6%) человек. Продолжительный эффект в течение периода времени до полутора лет был констатирован у 8 пациентов (25%), до 1 года – у 7 человек (21,8%), до 6 месяцев – у 5 (15,6%). Заключение. Инъекции в триггерные точки повышают эффективность терапии и обеспечивают длительный период ремиссии заболевания, что проявляется в отсутствии болевых приступов и ощущения дискомфорта. Научная новизна статьи Впервые для лечения миофасциального болевого синдрома (МБС) лица была использована методика с применением инъекций «Лимфомиозот» и «Траумель С» в триггерные точки. Установлено, что данная методика инъекций в триггерные точки является эффективным методом лечения МБС лица в независимости от причины, его вызвавшей. Показано, что применение инъекций в триггерные точки при миофасциальном болевом синдроме лица способствовало быстрому купированию болей и длительному безболевому периоду сроком наблюдения до двух лет.


2008 ◽  
Vol 6;11 (12;6) ◽  
pp. 885-889 ◽  
Author(s):  
Kenneth P. Botwin

Background: Myofascial pain is defined as pain that originates from myofascial trigger points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain generators. The myofascial pain syndrome is one of the largest groups of under diagnosed and under treated medical problems encountered in clinical practice. Trigger points are commonly seen in patients with myofascial pain which is responsible for localized pain in the affected muscles as well as referred pain patterns. Correct needle placement in a myofascial trigger point is vital to prevent complications and improve efficacy of the trigger point injection to help reduce or relieve myofascial pain. In obese patients, these injections may not reach the target tissue. In the cervicothoracic spine, a misguided or misplaced injection can result in a pneumothorax. Here, we describe an ultrasound-guided trigger point injection technique to avoid this potential pitfall. Office based ultrasound-guided injection techniques for musculoskeletal disorders have been described in the literature with regard to tendon, bursa, cystic, and joint pathologies. For the interventionalist, utilizing ultrasound yields multiple advantages technically and practically, including observation of needle placement in real-time, ability to perform dynamic studies, the possibility of diagnosing musculoskeletal pathologies, avoidance of radiation exposure, reduced overall cost, and portability of equipment within the office setting. To our knowledge, the use of ultrasound guidance in performing trigger point injection in the cervicothoracic area, particularly in obese patients, has not been previously reported. Methods: A palpable trigger point in the cervicothoracic musculature was localized and marked by indenting the skin with the tip of a plastic needle cover. The skin was then sterile prepped. Then, using an ultrasound machine with sterile coupling gel and a sterile latex free transducer cover, the musculature in the cervicothoracic spine where the palpable trigger point was detected was visualized. Then utilizing direct live ultrasound guidance, a 25-gauge 1.5 inch needle connected to a 3 mL syringe was placed into the muscle at the exact location of the presumed trigger point. This guidance helps confirm needle placement in muscle tissue and not in an adipose tissue or any other non-musculature structure. Results: The technique is simple to be performed by a pain management specialist who has ultrasound system training. Conclusion: Ultrasound-guided trigger point injections may help confirm proper needle placement within the cervicothoracic musculature. The use of ultrasound-guided trigger point injections in the cervicothoracic musculature may also reduce the potential for a pneumothorax by an improperly placed injection. Key words: Trigger point injection, myofascial pain, ultrasound


Sign in / Sign up

Export Citation Format

Share Document